Abstract
Sézary syndrome (SéS) represents a leukemic variant of cutaneous T-cell lymphoma, whose etiology is still unknown. To identify dyregulated genes in SéS, we performed transcriptional profiling of Sézary cells (SCs) obtained from peripheral blood of patients with SéS. We identified versican as the highest upregulated gene in SCs. VCAN is an extracellular matrix proteoglycan, which is known to interfere with different cellular processes in cancer. Versican isoform V1 was the most commonly upregulated isoform in SCs. Using a lentiviral plasmid, we overexpressed versican V1 isoform in lymphoid cell lines, which altered their growth behavior by promoting formation of smaller cell clusters and by increasing their migratory capacity towards stromal cell-derived factor 1, thus promoting skin homing. Versican V1 overexpression exerted an inhibitory effect on cell proliferation, partially by promoting activation-induced cell death. Furthermore, V1 overexpression in lymphoid cell lines increased their sensitivity to doxorubicin and gemcitabine. In conclusion, we confirm versican as one of the dysregulated genes in SéS and describe its effects on the biology of SCs. Although versican overexpression confers lymphoid cells with increased migratory capacity, it also makes them more sensitive to activation-induced cell death and some chemotherapeutics, which could be exploited further for therapeutic purposes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009. Clin Cancer Res 2012; 18: 5051–5060.
Dulmage BO, Geskin LJ . Lessons learned from gene expression profiling of cutaneous T-cell lymphoma. Br J Dermatol 2013; 169: 1188–1197.
Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197: 1477–1488.
van Doorn R, Dijkman R, Vermeer MH, Out-Luiting JJ, van der Raaij-Helmer EM, Willemze R et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004; 64: 5578–5586.
Cattaruzza S, Schiappacassi M, Ljungberg-Rose A, Spessotto P, Perissinotto D, Morgelin M et al. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J Biol Chem 2002; 277: 47626–47635.
Touab M, Villena J, Barranco C, Arumi-Uria M, Bassols A . Versican is differentially expressed in human melanoma and may play a role in tumor development. Am J Pathol 2002; 160: 549–557.
LaPierre DP, Lee DY, Li S-Z, Xie Y-Z, Zhong L, Sheng W et al. The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 2007; 67: 4742–4750.
Du WW, Yang W, Yee AJ . Roles of versican in cancer biology–tumorigenesis, progression and metastasis. Histol Histopathol 2013; 28: 701–713.
Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, Wight TN . Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol 2012; 31: 90–100.
Wight TN, Kang I, Merrilees MJ . Versican and the control of inflammation. Matrix Biol 2014; 35: 152–161.
Ricciardelli C, Sakko AJ, Ween MP, Russell DL, Horsfall DJ . The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 2009; 28: 233–245.
Wight TN, Kinsella MG, Evanko SP, Potter-Perigo S, Merrilees MJ . Versican and the regulation of cell phenotype in disease. Biochim Biophys Acta 2014; 1840: 2441–2451.
Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Reseace and Treatment of Cancer (EORTC). Blood 2007; 110: 479–484.
Dummer R, Nestle FO, Niederer E, Ludwig E, Laine E, Grundmann H et al. Genotypic, phenotypic and functional analysis of CD4+CD7+ and CD4+CD7- T lymphocyte subsets in Sezary syndrome. Arch Dermatol Res 1999; 291: 307–311.
Schwab C, Willers J, Niederer E, Ludwig E, Kundig T, Grob P et al. The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas. Br J Haematol 2002; 118: 1019–1026.
Kaltoft K, Bisballe S, Dyrberg T, Boel E, Rasmussen P, Thestrup-Pedersen K . Establishment of two continuous T-cell strains from a single plaque of a patient with mycosis fungoides. In Vitro Cell Dev Biol 1992; 28: 161–167.
Urosevic M, Fujii K, Calmels B, Laine E, Kobert N, Acres B et al. Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas. J Clin Invest 2007; 117: 2834–2846.
Saito R, Smoot ME, Ono K, Ruscheinski J, Wang P-L, Lotia S et al. A travel guide to Cytoscape plugins. Nat Methods 2012; 9: 1069–1076.
Montojo J, Zuberi K, Rodriguez H, Kazi F, Wright G, Donaldson SL et al. GeneMANIA Cytoscape plugin: fast gene function predictions on the desktop. Bioinformatics 2010; 26: 2927–2928.
Kumar M, Keller B, Makalou N, Sutton RE . Systematic determination of the packaging limit of lentiviral vectors. Hum Gene Ther 2001; 12: 1893–1905.
Lamant Le Reyniès A, Duplantier M-M, Rickman DS, Sabourdy F, Giuriato S et al. dGene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. Blood 2007; 109: 2156–2164.
Fang H, Liu J, Guo D, Liu P, Zhao Y . Epigenetic regulation of putative tumor suppressor TGFBI in human leukemias. Chin Med J (Engl) 2014; 127: 1645–1650.
Liu C, Li B, Cheng Y, Lin J, Hao J, Zhang S et al. MiR-21 plays an important role in radiation induced carcinogenesis in BALB/c mice by directly targeting the tumor suppressor gene Big-h3. Int J Biol Sci 2011; 7: 347–363.
Kondratiev S, Duraisamy S, Unitt CL, Green MR, Pinkus GS, Shipp MA et al. Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. Am J Surg Pathol 2011; 35: 1531–1539.
Teitell MA . The TCL1 family of oncoproteins: co-activators of transformation. Nat Rev Cancer 2005; 5: 640–648.
Zhao A, Yang Z, Sun R, Grinchuk V, Netzel-Arnett S, Anglin IE et al. SerpinB2 is critical to Th2 immunity against enteric nematode infection. J Immunol 2013; 190: 5779–5787.
Hirose J, Kawashima H, Yoshie O, Tashiro K, Miyasaka M . Versican interacts with chemokines and modulates cellular responses. J Biol Chem 2001; 276: 5228–5234.
Cardoso LEM, Little PJ, Ballinger ML, Chan CK, Braun KR, Potter-Perigo S et al. Platelet-derived growth factor differentially regulates the expression and post-translational modification of versican by arterial smooth muscle cells through distinct protein kinase C and extracellular signal-regulated kinase pathways. J Biol Chem 2010; 285: 6987–6995.
Nikitovic D, Zafiropoulos A, Katonis P, Tsatsakis A, Theocharis AD, Karamanos NK et al. Transforming growth factor-beta as a key molecule triggering the expression of versican isoforms v0 and v1, hyaluronan synthase-2 and synthesis of hyaluronan in malignant osteosarcoma cells. IUBMB Life 2006; 58: 47–53.
Rahmani M, Read JT, Carthy JM, McDonald PC, Wong BW, Esfandiarei M et al. Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells. J Biol Chem 2005; 280: 13019–13028.
Tufvesson E, Westergren-Thorsson G . Alteration of proteoglycan synthesis in human lung fibroblasts induced by interleukin-1beta and tumor necrosis factor-alpha. J Cell Biochem 2000; 77: 298–309.
Alizadeh AA, Bohen SP, Lossos C, Martinez-Climent JA, Ramos JC, Cubedo-Gil E et al. Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma 2010; 51: 1200–1216.
Pise-Masison CA, Radonovich M, Dohoney K, Morris JC, O'Mahony D, Lee MJ et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood 2009; 113: 4016–4026.
Rottiers P, Verfaillie T, Contreras R, Revets H, Desmedt M, Dooms H et al. Differentiation of EL4 lymphoma cells by tumoral environment is associated with inappropriate expression of the large chondroitin sulfate proteoglycan PG-M and the tumor-associated antigen HTgp-175. Int J Cancer 1998; 78: 503–510.
Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U, Hau P . The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 2007; 96: 1560–1568.
Su IJ, Kadin ME . Expression of growth factor/receptor genes in postthymic T cell malignancies. Am J Pathol 1989; 135: 439–445.
Petrey AC, de la Motte CA . Hyaluronan, a crucial regulator of inflammation. Front Immunol 2014; 5: 101.
Gill S, Wight TN, Frevert CW . Proteoglycans: key regulators of pulmonary inflammation and the innate immune response to lung infection. Anat Rec (Hoboken) 2010; 293: 968–981.
Wasa J, Nishida Y, Shinomura T, Isogai Z, Futamura N, Urakawa H et al. Versican V1 isoform regulates cell-associated matrix formation and cell behavior differentially from aggrecan in Swarm rat chondrosarcoma cells. Int J Cancer 2012; 130: 2271–2281.
Wang W, Xu G-L, Jia W-D, Ma J-L, Li J-S, Ge Y-S et al. Ligation of TLR2 by versican: a link between inflammation and metastasis. Arch Med Res 2009; 40: 321–323.
Lemire JM, Merrilees MJ, Braun KR, Wight TN . Overexpression of the V3 variant of versican alters arterial smooth muscle cell adhesion, migration, and proliferation in vitro. J Cell Physiol 2002; 190: 38–45.
Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng P-S et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005; 16: 1330–1340.
Hernández D, Miquel-Serra L, Docampo MJ, Marco-Ramell A, Bassols A . Role of versican V0/V1 and CD44 in the regulation of human melanoma cell behavior. Int J Mol Med 2011; 27: 269–275.
Onken J, Moeckel S, Leukel P, Leidgens V, Baumann F, Bogdahn U et al. Versican isoform V1 regulates proliferation and migration in high-grade gliomas. J Neurooncol 2014; 120: 73–83.
Planelles V, Jowett JB, Li QX, Xie Y, Hahn B, Chen IS . Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J Virol 1996; 70: 2516–2524.
Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW et al. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One 2010; 5: e13828.
Du WW, Yang BB, Yang BL, Deng Z, Fang L, Shan SW et al. Versican G3 domain modulates breast cancer cell apoptosis: a mechanism for breast cancer cell response to chemotherapy and EGFR therapy. PLoS One 2011; 6: e26396.
Klemke C-D, Brenner D, Weiβ E-M, Schmidt M, Leverkus M, Gülow K et al. Lack of T-cell receptor–induced signaling is crucial for CD95 ligand up-regulation and protects cutaneous T-cell lymphoma cells from activation-induced cell death. Cancer Res 2009; 69: 4175–4183.
Perego P, Corna E, De Cesare M, Gatti L, Polizzi D, Pratesi G et al. Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. Curr Med Chem 2001; 8: 31–37.
Mini E, Nobili S, Caciagli B, Landini I, Mazzei T . Cellular pharmacology of gemcitabine. Ann Oncol 2006; 17 (Suppl 5): v7–v12.
Acknowledgements
We thank Ines Kleiber-Schaaf for technical assistance in immunohistochemistry. This project was supported by research funding from Oncosuisse (Grant number OCS-01934-08-2006 to MU-M) and Kurt und Senta Herrmann-Stiftung (to MU-M). Microarray experiments and data acquisition were performed at Functional Genomics Center Zurich (http://www.fgcz.ch).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Fujii, K., Karpova, M., Asagoe, K. et al. Versican upregulation in Sézary cells alters growth, motility and resistance to chemotherapy. Leukemia 29, 2024–2032 (2015). https://doi.org/10.1038/leu.2015.103
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2015.103
This article is cited by
-
The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer
Journal of Cancer Research and Clinical Oncology (2022)
-
Blood and skin-derived Sezary cells: differences in proliferation-index, activation of PI3K/AKT/mTORC1 pathway and its prognostic relevance
Leukemia (2019)